YOU ARE LEAVING LUNDBECK.COM/IL

You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit.

CLICK HERE TO PROCEED TO

Cancel

At a Glance

Lundbeck in Brief

Lundbeck is a global pharmaceutical company specialized in developing innovative treatments for brain diseases. For more than 70 years, millions of people have been treated with our products and our development and distribution of pioneering therapies continues to make a difference to people worldwide.

Lundbeck in numbers

Global presence

We are headquartered in Denmark and located in more than 50 countries around the world. We have production facilities in Denmark, France, and Italy, and research centers in Denmark and US.

We have employees in more than 50 countries, and employ approximately 5,400 people across the value chain.

Ownership

In 1999, Lundbeck’s shares were listed on Nasdaq Copenhagen. Our largest shareholder is the Lundbeck Foundation, which holds approximately 70% of the shares. The Foundation annually grants about DKK 500 million to support medical research and educational and communication activities.

Key financial figures

Our 2022 revenue reached a total of DKK 18.2 billion.

Our largest markets are US, China, Canada, Spain, Italy, France, Japan, Brazil, Australia and South Korea.

In 2022, our total revenue from strategic brands was DKK 12.1 billion.

More from Lundbeck